(NewsDirect)
Theralase Technologies CEO RogerDuMoulin-White joined Steve Darling from Proactive to share details ofan update on the company's Phase II Non-Muscle Invasive BladderCancer clinical study.
DuMoulin-White shared the significant findings from the study,revealing that it has provided the primary study treatment to 63patients. The interim clinical data from Study II shows promisingresults, with a Complete Response (CR) rate of 54% at 6 months, 38% at12 months, and 37% at 15 months. These CR rates surpass the guidelinesset by the International Bladder Cancer Group (IBCG).
Additionally, at the 90 Day AssessmentVisit, 56% of Evaluable Patients achieved a CR, and 63% achieved aTotal Response (CR + IR). At 450 days, 37% achieved a CR, and 41%achieved a TR. The interim clinical data for patients who received theoptimized Study II Treatment is even more encouraging. At the 90 DayAssessment Visit, 62% of Evaluable Patients achieved a CR, and 68%achieved a Total Response (CR + IR). At 450 days, 39% achieved a CR,and 44% achieved a TR.
These positive results demonstrate thepotential of Theralase Technologies' treatment approach inaddressing Non-Muscle Invasive Bladder Cancer. The company continuesto advance its research and clinical studies, bringing hope topatients and the medical community alike.
ContactDetails
Proactive Canada
ProactiveCanada
+1 604-688-8158
Copyright (c) 2024 TheNewswire - All rights reserved.